[
  {
    "ts": "2025-11-10T06:04:51+00:00",
    "headline": "Walmart (WMT): Evaluating Valuation as Health and E-Commerce Moves Drive Analyst Optimism",
    "summary": "Walmart (WMT) is making headlines with several strategic moves, including a major collaboration to provide Eli Lilly’s Zepbound obesity treatment at its pharmacies. These initiatives highlight the company’s expanding role in healthcare and its enhanced e-commerce capabilities. See our latest analysis for Walmart. Walmart’s momentum is clearly building, fueled by a run of retail partnerships, digital health launches, and strategic logistics moves that continue to keep it in the spotlight. The...",
    "url": "https://finance.yahoo.com/news/walmart-wmt-evaluating-valuation-health-060451515.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5bfa6687-1864-386e-92f9-c665cf7db08e",
      "content": {
        "id": "5bfa6687-1864-386e-92f9-c665cf7db08e",
        "contentType": "STORY",
        "title": "Walmart (WMT): Evaluating Valuation as Health and E-Commerce Moves Drive Analyst Optimism",
        "description": "",
        "summary": "Walmart (WMT) is making headlines with several strategic moves, including a major collaboration to provide Eli Lilly’s Zepbound obesity treatment at its pharmacies. These initiatives highlight the company’s expanding role in healthcare and its enhanced e-commerce capabilities. See our latest analysis for Walmart. Walmart’s momentum is clearly building, fueled by a run of retail partnerships, digital health launches, and strategic logistics moves that continue to keep it in the spotlight. The...",
        "pubDate": "2025-11-10T06:04:51Z",
        "displayTime": "2025-11-10T06:04:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r4r1G1eFsl6QfUy6gLgJHg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nUAELTZkZtSvOC2PvSjdBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/walmart-wmt-evaluating-valuation-health-060451515.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/walmart-wmt-evaluating-valuation-health-060451515.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WMT"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T09:34:31+00:00",
    "headline": "SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases",
    "summary": "SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.",
    "url": "https://www.pharmaceutical-technology.com/news/sanegenebio-lilly-rnai-licensing-deal/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "13183824-c983-379b-a43a-0e431e9f2a02",
      "content": {
        "id": "13183824-c983-379b-a43a-0e431e9f2a02",
        "contentType": "STORY",
        "title": "SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases",
        "description": "",
        "summary": "SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.",
        "pubDate": "2025-11-10T09:34:31Z",
        "displayTime": "2025-11-10T09:34:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/592a0da246107755dbf22c0c00aba0d5",
          "originalWidth": 1440,
          "originalHeight": 812,
          "caption": "SanegeneBio pipeline features experimental treatments for cardiometabolic conditions",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjZc0yDiT_LqG1mGmyb3mg--~B/aD04MTI7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/592a0da246107755dbf22c0c00aba0d5.cf.webp",
              "width": 1440,
              "height": 812,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_8U_5jt8oe1aTOiIv2TJBA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/592a0da246107755dbf22c0c00aba0d5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/sanegenebio-lilly-rnai-licensing-deal/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sanegenebio-lilly-sign-rnai-licence-093431595.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T04:33:52+00:00",
    "headline": "2 Growth Stocks with All-Star Potential and 1 We Question",
    "summary": "Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.",
    "url": "https://finance.yahoo.com/news/2-growth-stocks-star-potential-043352171.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "7165ce2f-8fe2-3a7a-a332-48252a30a9dd",
      "content": {
        "id": "7165ce2f-8fe2-3a7a-a332-48252a30a9dd",
        "contentType": "STORY",
        "title": "2 Growth Stocks with All-Star Potential and 1 We Question",
        "description": "",
        "summary": "Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.",
        "pubDate": "2025-11-10T04:33:52Z",
        "displayTime": "2025-11-10T04:33:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/d8f64cd512750e81ddb9293784033ffe",
          "originalWidth": 2400,
          "originalHeight": 1603,
          "caption": "DDOG Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u.pYFSeNAk6XGh8hFOPaw--~B/aD0xNjAzO3c9MjQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/stockstory_922/d8f64cd512750e81ddb9293784033ffe.cf.webp",
              "width": 2400,
              "height": 1603,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/avylLmnwtDoHvc_qca5ARQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/d8f64cd512750e81ddb9293784033ffe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-growth-stocks-star-potential-043352171.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-growth-stocks-star-potential-043352171.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "USPH"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "DDOG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T09:18:45+00:00",
    "headline": "Novo Rises After Bowing Out of Metsera Takeover Battle",
    "summary": "Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday morning after Pfizer matched its latest offer in a bidding war that had pushed the price to levels that caused concern the bidders might be overpaying.  Adding to Novo’s obstacles, Metsera said it got a call from the US Federal Trade Commission flagging potential regulatory risks with the proposed Novo deal structure.  Pfizer agreed to pay $65.60 a share in cash for Metsera, as well as up to $20.65 a share contingent on certain milestones.",
    "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
      "content": {
        "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
        "contentType": "STORY",
        "title": "Novo Rises After Bowing Out of Metsera Takeover Battle",
        "description": "",
        "summary": "Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday morning after Pfizer matched its latest offer in a bidding war that had pushed the price to levels that caused concern the bidders might be overpaying.  Adding to Novo’s obstacles, Metsera said it got a call from the US Federal Trade Commission flagging potential regulatory risks with the proposed Novo deal structure.  Pfizer agreed to pay $65.60 a share in cash for Metsera, as well as up to $20.65 a share contingent on certain milestones.",
        "pubDate": "2025-11-10T09:18:45Z",
        "displayTime": "2025-11-10T09:18:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fmXrJtbI3H5zCMXkv.hLZw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2i3MlmOJYQDWFClE3QXhFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T11:13:44+00:00",
    "headline": "Did Walmart's (WMT) New Healthcare and Logistics Moves Just Shift Its Investment Narrative?",
    "summary": "Walmart recently expanded its health and wellness offerings by partnering with Eli Lilly to provide direct-to-consumer access for the weight-loss drug Zepbound in its pharmacies, while also integrating GOFO's nationwide logistics services to strengthen its e-commerce marketplace delivery capabilities. These collaborations underscore Walmart’s drive to enhance healthcare access and delivery efficiency, reflecting a multi-faceted approach to digital transformation and marketplace...",
    "url": "https://finance.yahoo.com/news/did-walmarts-wmt-healthcare-logistics-111344844.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "1ade6a88-af24-36b9-9ac3-91d17d0ecbdc",
      "content": {
        "id": "1ade6a88-af24-36b9-9ac3-91d17d0ecbdc",
        "contentType": "STORY",
        "title": "Did Walmart's (WMT) New Healthcare and Logistics Moves Just Shift Its Investment Narrative?",
        "description": "",
        "summary": "Walmart recently expanded its health and wellness offerings by partnering with Eli Lilly to provide direct-to-consumer access for the weight-loss drug Zepbound in its pharmacies, while also integrating GOFO's nationwide logistics services to strengthen its e-commerce marketplace delivery capabilities. These collaborations underscore Walmart’s drive to enhance healthcare access and delivery efficiency, reflecting a multi-faceted approach to digital transformation and marketplace...",
        "pubDate": "2025-11-10T11:13:44Z",
        "displayTime": "2025-11-10T11:13:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r4r1G1eFsl6QfUy6gLgJHg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nUAELTZkZtSvOC2PvSjdBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/did-walmarts-wmt-healthcare-logistics-111344844.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-walmarts-wmt-healthcare-logistics-111344844.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WMT"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T11:06:27+00:00",
    "headline": "Novo's $1,349 Shot Just Got Squeezed: Is Lilly Winning the Weight-Loss War?",
    "summary": "Novo Nordisk is under pressure from cheap copycats, a Trump pricing deal, and Lilly's fast-growing Zepbound juggernaut.",
    "url": "https://finance.yahoo.com/news/novos-1-349-shot-just-110627397.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "a3532613-b722-3f7a-8910-c512b710acfc",
      "content": {
        "id": "a3532613-b722-3f7a-8910-c512b710acfc",
        "contentType": "STORY",
        "title": "Novo's $1,349 Shot Just Got Squeezed: Is Lilly Winning the Weight-Loss War?",
        "description": "",
        "summary": "Novo Nordisk is under pressure from cheap copycats, a Trump pricing deal, and Lilly's fast-growing Zepbound juggernaut.",
        "pubDate": "2025-11-10T11:06:27Z",
        "displayTime": "2025-11-10T11:06:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9TzR39bxuUCR99sbuZJDMQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjQrAqlrjUwsW.v1rUBg.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novos-1-349-shot-just-110627397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novos-1-349-shot-just-110627397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]